Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer

被引：0

作者：

Bohmer, Dirk ^{[1
]}

Gruen, Arne ^{[2
]}

机构：

[1] Charite, Dept Radiat Oncol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany

[2] Charite, Dept Radiat Oncol, Campus Virchow Klinikum, Berlin, Germany

来源：

CURRENT ONCOLOGY REPORTS | 2021年 / 23卷 / 02期

关键词：

Bladder cancer; Trimodality treatment; Neoadjuvant chemotherapy; PHASE-III TRIAL;

D O I：

10.1007/s11912-020-01012-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We comment on the paper of Di Maria Jiang et al. published in Current Oncology Reports 2020, https://doi.org/10.1007/s11912020-0880-5. We disagree on a major recommendation of the authors because of lacking evidence. This response is considered to be important for readers of Current Oncology Reports.

引用

页数：2

共 2 条

[1] International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
Griffiths, Gareth
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2171 - 2177
[2] Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03
Shipley, WU
Winter, KA
Kaufman, DS
Lee, WR
Heney, NM
Tester, WR
Donnelly, BJ
Venner, PM
Perez, CA
Murray, KJ
Doggett, RS
True, LD
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) : 3576 - 3583

← 1 →